MancardiGLSormaniMPDi GioiaM. Autologous haematopoietic stem cell transplantation with an intermediate conditioning regimen in multiple sclerosis: The Italian multi-centre experience. Mult Scler J2012; 18: 835–842.
3.
ShevchenkoJLKuznetsovANIonovaTI. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol2012; 40: 892–898.
4.
BowenJDKraftGHWundesA. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: Long-term results. Bone Marrow Transplant2012; 47: 946–951.
5.
BurtRKBalabanovRHanX. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA2015; 313: 275–284.
6.
CurroDVuoloLGualandiF. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. Mult Scler J2015; 21: 1423–1430.
7.
NashRAHuttonGJRackeMK. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): A 3-year interim report. JAMA Neurol2015; 72: 159–169.
8.
MancardiGLSormaniMPGualandiF. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. Neurology2015; 94: 981–988.
9.
ShevchenkoJLKuznetsovANIonovaTI. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: Physician’s and patient’s perspectives. Ann Hematol2015; 94: 1149–1157.
10.
AtkinsHLBowmanMAllanD. Immunoablation and autologous haematopoietic stem-cell transplantation for aggressive multiple sclerosis: A multicenter single-group phase 2 trial. Lancet. Epub ahead of print 9June2016. DOI: 10.1016/S0140-6736(16)30169-6.
